Light Sciences Oncology Meets A Major Milestone In Aptocine Development With Target Enrollment In Phase 3 MCRC Trial
Light Sciences Oncology, Inc. (LSO) announced the achievement of a major milestone in its late-stage clinical development of Aptocine™ (talaporfin sodium) for treatment of solid tumors. LSO’s global Phase 3 trial of Aptocine in metastatic colorectal cancer (MCRC) has reached target enrollment of 450 patients at 52 sites. The controlled, randomized MCRC trial is being conducted to assess the …
Read more on Medical News Today
Rodney Alcala’s Final Revenge
UPDATE, 2-25-2010: “Guilty Verdict for Serial Killer and “The Dating Game” Contestant Rodney Alcala.” In 2005, when DNA evidence linked alleged serial killer Rodney Alcala…
Read more on LA Weekly